Skip to main content

Mission of the Program in Cancer Biology

To train new leaders in the field of Cancer Biology that will develop new knowledge that will translate into improved detection, diagnosis, prognosis, prevention, or treatment of cancer.

Research Areas of Emphasis

  • Cancer Immunity, host tumor interactions, and angiogenesis
  • Cancer Precision Medicine—targeted therapies and drug resistance using mouse modeling, human tumor tissues, and systems approaches
  • Bioinformatic analyses of tumor heterogeneity including genome, proteome, metabolome, and immunome components during tumor progression
  • Basic Cancer Biology—tumor progression, invasion and metastasis

Steering Committee

Ann Richmond, Program Director

Jin Chen, Director of Graduate Studies

Roger Chalkley

Barbara Fingleton

Hal Moses

Kimryn Rathmell

Julie Sterling

Alissa Weaver

Chris Williams


News & Events


KRT-232, is a promising new drug for patients that do not respond to the standard therapy for Metastatic Melanoma. The Richmond lab found certain genetic mutations, including one that’s routinely screened, that could serve as an indicator for which patient will respond to which therapeutic strategy. Research Discovery

Vandana Abramson, MD, is showing new data that PARP inhibitors are promising for patients without BRCA-mutated cancers. Research is currently underway in a clinical trial led by Crispens at Vanderbilt-Ingram that uses PARP inhibitors in patients with non-BRCA mutated recurrent ovarian cancer. Learn about this Clinical Trial Research.